Answers are grounded in this paper and cite their sources.
Epidemiological analysis reveals serotype-specific immune gaps for dengue vaccines in India, highlighting the need for phased deployment aligned with circulating regional strains.
India’s approval of TAK-003 (Qdenga) on July 20, 2026, marks a defining moment in dengue prevention, yet four-serotype complexity demands a calibrated rather than uniform strategy. Built on a live-attenuated DENV-2 backbone, TAK-003 generates lower type-specific neutralising antibody titres — most critically against DENV-3 — an imbalance compounded by original antigenic sin, which may further limit cellular priming against DENV-3 and DENV-4. India’s epidemiology amplifies these concerns: DENV-3 accounted for nearly 80% of typed cases in Bengaluru in 2024 — a regional signal, though serotype dominance varies across States — and large seronegative peri-urban populations remain vulnerable. NIH TV003-derived vaccines, including India’s DengiAll in Phase 3, incorporate attenuated strains of all four serotypes, offering potentially broader immunity. TAK-003’s demonstrated efficacy against severe dengue and hospitalisation — including in seronegative participants — makes it a valuable first-line tool. We argue for a phased, serotype-informed strategy: deploy TAK-003 now, while building surveillance capacity for vaccines with potentially broader serotype coverage.
No takes yet. Share an insight, caveat, or question.
Vashishtha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: